PF-06741086 for Hemophilia
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, it mentions that participants should not be on certain therapies like regular immunomodulatory drugs or prophylaxis with bypassing agents during the study. It's best to discuss your specific medications with the study team.
How is the drug PF-06741086 different from other hemophilia treatments?
PF-06741086 is unique because it is a monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI), which is different from traditional treatments that replace missing clotting factors. This approach helps initiate clotting through the extrinsic pathway, offering a novel mechanism for managing hemophilia.12345
What is the purpose of this trial?
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
Adults and teens with severe Hemophilia A or moderately to severely severe Hemophilia B, weighing at least 35 kg. They must have a history of compliance with their current treatment regimen, no inhibitors for non-inhibitor cohort, or specific inhibitor criteria for the inhibitor cohort. Exclusions include planned surgeries, other hemostatic defects, abnormal organ function, certain drug therapies including gene therapy for hemophilia.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants continue their current hemophilia regimen to establish a baseline
Treatment
Participants receive PF-06741086 once weekly subcutaneous administration
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PF-06741086
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University